Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | CA7 | P43166 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | FABP3 | P05413 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30536599 | 1.00 | CA12 (0.69) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8381593 | 0.89 | CA12 (0.74) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3901924 | 0.88 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31019062 | 0.88 | FGFR1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25285914 | 0.87 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6634531 | 0.86 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7755637 | 0.86 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14052509 | 0.83 | SMN1; SMN2 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3996413 | 0.83 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9138778 | 0.83 | KDM4E (0.54) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023079616-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | シャープディスプレイテクノロジー株式会社 | 2023-05-11 | — | — | WO | claimed |
| EP-0794789-A4 | INHIBITORS OF PRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 1999-05-26 | — | — | EP | claimed |
| EP-0794789-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-09-17 | — | — | EP | claimed |
| WO-1996021456-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1996-07-18 | — | — | WO | claimed |
| WO-2023079616-A1 | LIGHT EMITTING ELEMENT, PRODUCTION METHOD FOR LIGHT EMITTING ELEMENT, DISPLAY DEVICE, AND PRODUCTION METHOD FOR DISPLAY DEVICE | シャープディスプレイテクノロジー株式会社 | 2023-05-11 | — | — | WO | disclosed |
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
| EP-1425015-A4 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1425015-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003015715-A2 | TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | CA12 2423/4885CA1 1469/4885CA2 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.